Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
about
Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitorsJuvenile Idiopathic Arthritis in the Era of International Cooperation.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Summary of worldwide pediatric malignancies reported after exposure to etanercept.Nutritional supplementation and dietary restriction in the resolution of enthesitis-related arthritis.Juvenile idiopathic arthritis-associated uveitis.The development and assessment of biological treatments for children.Current medical treatments for juvenile idiopathic arthritis.Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in TaiwanCost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain.A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide.Rates of malignancy associated with juvenile idiopathic arthritis and its treatmentTofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension studyErosion or normal variant? 4-year MRI follow-up of the wrists in healthy childrenUpdate on the treatment of juvenile idiopathic arthritisDisease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Biologics in children's autoimmune disorders: efficacy and safety.Emerging drugs to treat juvenile idiopathic arthritis.Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.Optimization of pediatric rheumatology therapeutics.Update on biologicals for treatment of juvenile idiopathic arthritis.Infectious complications in juvenile idiopathic arthritis.Biologic response modifiers and pediatric psoriasis.Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.Biologic-associated infections in pediatric rheumatology.Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Management of Juvenile Idiopathic Arthritis: A Clinical Guide.Juvenile idiopathic arthritis: management and therapeutic options.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.MRI of the wrist in juvenile idiopathic arthritis: erosions or normal variants? A prospective case-control study.Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).
P2860
Q29302324-E65FC94C-75FC-4155-9FB3-AB9F71418BA4Q30235998-D4AAA978-CA74-40ED-A5DF-3EE0C24A1CEFQ33765738-F43E22EA-8FB4-4C67-904E-2B8B6F70A263Q33998050-D1C9C383-A5FD-4DF0-9417-2F747E6F8F81Q34904542-0B92ED45-D4D6-473E-9B5C-4F15DD519372Q34950552-C8CBB1DC-59DE-4F43-8B08-7053C616C99CQ35135936-9D37A7D4-3E2F-441B-A75E-87640542427DQ35294398-3E0100E2-031C-4D64-9113-E242FCA46926Q35654296-3549C86D-8161-4E36-AF68-F3B7ABD93803Q35795354-D4576927-9376-4B76-8954-1422F763A9A6Q35824809-E654297E-419E-4658-A445-DBC0463B2B3CQ35861269-11A503E7-466D-4356-9FE2-B367E6353434Q36513512-6B6283FF-7C75-41FA-88EB-416BEF9EFCBDQ36620571-3F86E3BB-990A-4560-8E14-FC70487A9249Q37060351-EF609516-21A1-4B76-864F-D774D13133A5Q37147226-28E9F139-BAF3-408A-B90E-9A2AF94A9542Q37320554-1F57E96B-5BAD-446A-A67B-940974873591Q37463702-2ED8AC2F-C7E5-4D5A-8B57-3C407561E6D6Q37765830-B84408E6-5C18-4700-A36A-B4348A2C8E13Q37870209-0E507B40-0AE1-43B1-94C5-4E256D069EADQ37894016-63D21F77-AFEF-4B88-8160-B933756164BFQ37991520-DEB12535-F769-4745-89B4-00310015EBE5Q38071693-430E4D86-0A49-4EA2-8C40-DC94A2FC23ECQ38093095-6199CA2F-30A7-45E9-B83D-7C3ED7807556Q38366432-FC349C4C-A003-434A-80EA-14824BBAF6EDQ38530469-16209AAB-09C1-4BA2-9ACD-02334340B757Q38589392-F7BA8B93-9A97-4611-A170-4599F66A5C2DQ38591278-8D81DCED-B3C6-4200-AD2A-13DDBA201F98Q38711172-627E959F-18AB-4F5E-B2A2-3959B67459DCQ38916421-65965C74-F096-4830-92BF-5305329E2838Q39243858-58B7BF87-889E-4F38-BE53-651F047464C2Q39371316-016B7C08-5EDC-45FD-84F3-4E81ACA4DA9FQ40179129-F131AC38-0EC2-46A5-8068-34AFEF3BD5AAQ40179378-7DC214A2-4457-4977-B8F5-2054ECF1B9F5Q41600541-7C22CBFB-20C0-4253-AA60-CDCAF2FE6627Q45535646-EF55ADF3-C3F3-4F72-8415-8B90E51FE094Q48505199-A435FB39-0E22-4414-B8E5-894C596AA284Q50065301-452C0A48-BB72-4AAA-8503-CFBC6308925FQ51550151-4A7D42B3-F201-438B-93CA-951820EDB8C8Q54144614-8205D8B7-CC3D-4E4D-B33C-33B6DACCDE52
P2860
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Long-term efficacy and safety ...... pen-label treatment extension.
@ast
Long-term efficacy and safety ...... pen-label treatment extension.
@en
Long-term efficacy and safety ...... pen-label treatment extension.
@nl
type
label
Long-term efficacy and safety ...... pen-label treatment extension.
@ast
Long-term efficacy and safety ...... pen-label treatment extension.
@en
Long-term efficacy and safety ...... pen-label treatment extension.
@nl
prefLabel
Long-term efficacy and safety ...... pen-label treatment extension.
@ast
Long-term efficacy and safety ...... pen-label treatment extension.
@en
Long-term efficacy and safety ...... pen-label treatment extension.
@nl
P2093
P2860
P356
P1476
Long-term efficacy and safety ...... open-label treatment extension
@en
P2093
Adedigbo Fasanmade
Alan Mendelsohn
Alberto Martini
Daniel J Lovell
Earl D Silverman
Edward H Giannini
Ivan Foeldvari
Joachim Oppermann
Joyce Davidson
Lisa Imundo
P2860
P304
P356
10.1136/ARD.2009.100354
P407
P577
2010-04-01T00:00:00Z